The FDA approved a new generic version of the medical abortion pill mifepristone, marketed by Evita Solutions LLC, validating bioequivalence to the original product Mifeprex. This decision comes amid political tensions surrounding abortion access under the Trump administration. The generic approval broadens options for medical abortion, with mifepristone remaining a key agent in reproductive healthcare despite societal and regulatory controversies.